FDA Warns Against Usage of Needle Free Flu Vaccine

January 3rd, 2012|

Recently, US Food and Drug Administration (FDA) has advised health providers not to use needle free injector devices to administer influenza vaccines, because so far no flu vaccines have been approved for administration using such devices, saying they are approved for only the measles, mumps and rubella vaccine.

Size of Indian Pharma Market

January 3rd, 2012|

Structure / Market Size The US Sector $ 12 billion valued pharmaceutical industry in India is expected to grow at an compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).

Air freshener dangerous to health

December 13th, 2011|

Air fresheners which are used for clean refreshing house or car may smells sweet but very few people understand how bad air fresheners are for their health. Science has confirmed that though air freshener smells sweet but they may cause lung cancer. People with asthma or allergies may want to avoid air fresheners and other chemicals used to spread fragrant scents through their homes, and their doctors should be aware of the hazards.

Coffee lowers risk of Skin Cancer

December 2nd, 2011|

According to a research by American Association for Cancer Research, people who drink coffee are at a reduced risk of developing Basal Cell Carcinoma, the most common form of skin cancer. And the more they drink lesser the risk !!

Cipla retains top slot in domestic pharma market

February 8th, 2010|

Drug company Cipla maintained its top position in the domestic market for the 12 months ended December, 2009, with a market share of 5.38 per cent — up 18 per cent over the year and ahead of Ranbaxy Laboratories and GlaxoSmithKline (GSK).

No place like home, finds Indian pharma

February 7th, 2010|

In a recent reversal, operations abroad are hampering profit.

Pharma deals in India: 2009 precursor to what 2010 holds

December 30th, 2009|

For the pharmaceutical sector, 2009 was a year when Indian manufacturing capabilities took centre stage. For the first time, global pharmaceutical giants like Pfizer and GlaxoSmithKline (GSK) came shopping for Indian manufacturers. recaps some of biggest inbound pharma deals this year.

FMCG, pharma fledglings in for better days

December 20th, 2009|

The market has recently seen the re-rating of small companies in the FMCG and pharma sectors. FMCG players Dabur India and Emami witnessed the stocks of their recently-acquired companies, Fem Care Pharma and Zandu Pharma getting re-rated. Similarly, pharma companies, Cadila Care and Elder Pharma, have seen a lot of price action in the stocks of Zydus Wellness and Elder Health Care, respectively which were hived-off into independent companies respectively.

Modi asks pharma cos to focus on real research

December 15th, 2009|

“In this age of product-process patent and intellectual property rights, discovery of new drugs holds significance. Moreover, a social environment, under which the firms follow the rule at their own, should also be created. If this is not done, it will make way for the rise of holistic healthcare culture in India too,” said Gujarat’s Chief Minister Narendra Modi.

Mexico plans world-class medical research hub

December 6th, 2009|

Mexico City has announced plans for what it hopes will be a world-class centre for biomedical and nano-medical research. To be called Campus Biometropolis, the city hopes the new centre will attract investment and become an "engine for the transformation" of Mexico's economy.

Avon to gain from nod to Ranbaxy’s drug

December 6th, 2009|

Ranbaxy Laboratories exclusive launch of generic anti-herpes Valtrex (valacyclovir hydrochloride) tablets in the US will help a listed Indian drug company, Hyderabad-based Avon Organics.

In healthcare, we can at best play catch-up with China

November 19th, 2009|

Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.


November 9th, 2009|

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts.

US health bill to benefit local generic firms

November 9th, 2009|

The US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promise for generic manufacturers from India.

A 360 Degree Perspective for CEOs to drive Growth, Innovation and Leadership,

October 25th, 2009|

Companies seem to be hesitating in moving ahead as they wait for further improvements in the global economy. However, Frost & Sullivan believes that the best CEOs are already planning how their businesses will take advantage of the growth opportunities presented by the rebound.

Drug MNCs look at India as a market

October 6th, 2009|

The list of drug majors scouting for a suitable buy in India is long. But this time, the attraction is: India as a market, and not merely as an inexpensive destination to source and produce products, say consultants and lawyers observing the increased merger and acquisition (M&A) activity seen in the pharmaceutical space.

Pfizer plans major push into generics

September 10th, 2009|

Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market.

Big pharma companies join outsourcing queue

August 18th, 2009|

India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing

Sandoz launches first generic version of Prograf capsules

August 10th, 2009|

Sandoz today announced the introduction of tacrolimus capsules, a generic equivalent of Prograf®, in the US. Tacrolimus is an immunosuppressive treatment used to help prevent rejection of a kidney or liver transplant.

Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head

July 27th, 2009|

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology.